Stock EQL EQL PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

All News EQL Pharma AB

Equities

EQL

SE0005497732

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 18:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
44.8 SEK +1.36% Intraday chart for EQL Pharma AB +3.46% +34.13%
04-22 EQL Pharma AB Announces Mellozzan Launched in Germany and Austria CI
02-13 EQL Pharma AB Provides Sales Guidance for the Year 2023/24 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2023/24
AQ
Mellozzan[® ](melatonin) launched in Germany and Austria
AQ
EQL Pharma AB Announces Mellozzan Launched in Germany and Austria
CI
Mellozzan[® ](melatonin) have gained marketing approval in the UK
AQ
Nomination committee for the 2024 Annual General Meeting
AQ
EQL Pharma: Q3 numbers supportive of inflection point
AQ
Interim Report April - December 2023
AQ
EQL Pharma AB Provides Sales Guidance for the Year 2023/24
CI
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Invitation to presentation in connection with EQL Pharma's quarterly report, third quarter, 2023/24
AQ
EQL Pharma: Growth and margin inflection point – Q3(23/24) preview
AQ
EQL Pharma: A repeat prescription for growth
AQ
EQL Pharma again appointed Gazelle company in Skåne by Dagens Industri and once again places itself in 6th place out of 98 Skåne Gazelles
AQ
Interim Report April - September 2023
AQ
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Invitation to presentation in connection with EQL Pharma's quarterly report, second quarter, 2023/24
AQ
EQL Pharma Plans 2024 Launch of Melatonin Product in Germany, Austria After Marketing Approvals
MT
Mellozzan[® ](melatonin) have gained marketing approval in Germany and Austria
AQ
EQL Pharma AB Announces its Mellozzan Gains Marketing Approval by Health Authorities in Germany and Austria
CI
EQL Pharma : Annual report 2022/2023
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EQL Stock
  4. News EQL Pharma AB